Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Reprod Med ; 41(9): 645-52, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8887188

ABSTRACT

OBJECTIVE: To study the beneficial effects of oral contraceptive (OC) therapy following gonadotropin-releasing hormone agonist (GnRH-a) administration in women with polycystic ovary disease (PCOD). STUDY DESIGN: Twenty-three hyperandrogenic women (aged 15-39) were randomized into two groups; GnRH-a (depot every 28 days) for six months or combination therapy (GnRH-a plus OC "addback") for six months. Following six months of treatment with either therapy, all patients received OC therapy for at least six months. The hormonal state was evaluated at three-month intervals. RESULTS: Hormone levels of luteinizing hormone (LH), testosterone (T) and free T remained suppressed within the normal range in 11 of 17 patients (65%) during the six months of OC only therapy, while the other six patients showed "escape" from suppression, with the LH, T and free T concentrations rising to pre-GnRH-a treatment levels. Use of OC addback therapy did not potentiate the long-acting therapeutic effect of GnRH-a pretreatment; three of six patients in the escape group were pretreated with combination therapy and three with GnRH-a only. CONCLUSION: In the majority of women with PCOD, OC therapy following GnRH-a administration was effective in maintaining ovarian androgen suppression. Failure to maintain ovarian suppression in this patient population was associated with higher elevations of baseline free T concentrations.


PIP: Clinical investigators randomly allocated 24 hirsute women aged 15-39 years with polycystic ovary disease (PCOD) to either the treatment program offering an injection of leuprolide acetate (a highly potent gonadotropin-releasing hormone agonist [GnRH-a]) for depot suspension (3.75 mg) at 28-day intervals for six months or the treatment program offering both the same injection and a combined oral contraceptive (OC) as add-back for six months. At three months, one woman moved out of state and withdrew from the study. After six months of either GnRH-a treatment regimen, all remaining 23 women received only OCs for six more months. Six women did not successfully complete the OC therapy and were excluded from the statistical analyses. The investigators aimed to examine the benefits of OC use in the management of women with PCOD after six months of pretreatment with the GnRH-a. During the OC-only treatment period, 11 (65%) of 17 patients still had suppressed levels of luteinizing hormone (LH), testosterone (T), and free T within the normal range. These levels increased to pre-GnRH-a treatment levels in the remaining six women, indicating escape from ovarian suppression. Three of six women in the escape group received combination therapy for pretreatment, while the other three received only GnRH-a. The women in the escape group had a higher baseline free T concentration than the suppressed group (5.1 vs. 3.3 ng/dl; p = 0.02). The findings revealed that OC therapy following GnRH-a administration effectively maintained ovarian androgen suppression in most women with PCOD. They also indicated that failure to maintain this suppression had a significant association with higher baseline free T concentrations.


Subject(s)
Contraceptives, Oral/therapeutic use , Leuprolide/therapeutic use , Polycystic Ovary Syndrome/drug therapy , Adolescent , Adult , Drug Therapy, Combination , Female , Humans , Hyperandrogenism/etiology , Luteinizing Hormone/blood , Polycystic Ovary Syndrome/blood , Polycystic Ovary Syndrome/complications , Testosterone/blood , Time Factors
2.
Fertil Steril ; 66(1): 54-60, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8752611

ABSTRACT

OBJECTIVE: To determine if continuous oral contraceptive (OC) therapy was superior to a cyclic regimen in achieving persistent pituitary suppression of LH in patients with polycystic ovary syndrome (PCOS). DESIGN: Fourteen women (ages 16 to 41 years) with PCOS received one of three treatment groups: continuous OC therapy (30 micrograms ethinyl E2 plus 150 micrograms desogestrel), cyclic OC therapy, or monthly injections of a GnRH agonist (GnRH-a, leuprolide acetate depot 3.75 mg) for 3 months. Basal hormone levels were obtained before initiating therapy, on days 15 to 17 of the 3rd month of treatment (study 1) and again on days 26 to 28 of the 3rd month (study 2). A GnRH stimulation test was also performed during study 1 and study 2. RESULTS: After 3 months of treatment, LH levels were decreased significantly in all groups with less effective suppression observed in the cyclic OC group compared with the continuous OC or GnRH-a groups. A significant rise in LH was found only in the cyclic OC group after 5 to 7 days of placebo treatment (study 1 versus study 2). An increase in T was also observed in the cyclic OC group during study 2, whereas the continuous OC and GnRH-a groups showed continued inhibition of T levels. Although there was no significant difference in LH area under the curve (AUC) measurements after GnRH stimulation in study 1 versus study 2, the LH AUC was significantly greater in both studies in the cyclic OC group compared with the continuous OC or GnRH-a groups. CONCLUSIONS: Increased LH secretion during the week of placebo in the cyclic OC group was associated with a concomitant increase in T. The striking rise in LH secretion after GnRH stimulation in the cyclic OC group may represent increased pituitary sensitivity in patients receiving cyclic OCs regardless of the phase of the treatment cycle, perhaps secondary to increased pituitary stores of LH in these women.


PIP: Clinical researchers recruited 16 women aged 16-41 diagnosed with polycystic ovary syndrome (PCOS) for a study designed to compare their pituitary responsiveness to exogenous gonadotropin releasing hormone (GnRH) stimulation after three months of therapy with either the continuous or cyclic regimen of combined oral contraceptives (OCs). The three treatments included six women on continuous therapy (i.e., every day for 3 months) with an OC containing 30 mcg ethinyl estradiol and 150 mcg desogestrel, six women on cyclic therapy (i.e., 21 days of OC therapy with 7 days of placebo over 3 months) with the same OC formulation, and four women on therapy with a GnRH agonist (GnRH-a), Lupron depot (3.75 mg leuprolide acetate). Luteinizing hormone (LH) levels fell significantly in all groups between baseline and three months treatment (p 0.001). Cyclic OCs exerted a less effective LH suppression than the continuous OC and the GnRH-a, however (88% vs. 99%; p 0.05). Only the cyclic OC group experienced a significant increase in LH after 5-7 days of placebo treatment (126% increase; p 0.008). The percent change in LH levels was significantly different between the cyclic and continuous OC groups (p 0.03) and between the cyclic OC and GnRH-a groups (p 0.01). Similarly, the cyclic OC group had an increase in testosterone levels after 5-7 days of placebo treatment (86% increase), while the other two groups had no change. When both the cyclic and continuous OC groups received their first GnRH stimulation test on days 15-17 of the third 28-day cycle and on days 26-28 (5-7 days of placebo in the OC cyclic group), the LH area under the curve (AUC) measurements were much greater in the cyclic OC group than the continuous OC and the GnRH-a groups (p 0.004). This event suggests increased pituitary sensitivity in patients receiving cyclic OCs regardless of the phase of the treatment cycle; which may be secondary to increased pituitary stores of LH in women with PCOS. These findings support the theory that LH contributes greatly to ovarian testosterone secretion in women with PCOS.


Subject(s)
Contraceptives, Oral/administration & dosage , Leuprolide/therapeutic use , Menstrual Cycle , Pituitary Gland/physiopathology , Polycystic Ovary Syndrome/drug therapy , Polycystic Ovary Syndrome/physiopathology , Adolescent , Adult , Contraceptives, Oral/therapeutic use , Drug Administration Schedule , Female , Gonadotropin-Releasing Hormone/agonists , Hormones/blood , Humans
3.
Fertil Steril ; 63(5): 970-8, 1995 May.
Article in English | MEDLINE | ID: mdl-7720941

ABSTRACT

OBJECTIVE: To determine if combination GnRH agonist (GnRH-a) and oral contraceptive (OC) therapy was more effective than GnRH-a or OC alone in the treatment of hirsute women with ovarian hyperandrogenism. DESIGN: Thirty-three hirsute women (ages 15 to 39 years) were randomized into three groups: 3.75 mg IM leuprolide acetate (LA) depot every 28 days for 6 months, combination monophasic oral contraceptive for 6 months (OC), or GnRH-a plus OC for 6 months (LA + OC). MAIN OUTCOME MEASURES: Comparative studies of changes in hormonal and hair parameters were performed at baseline, 3, and 6 months after starting therapy. RESULTS: After 6 months, serum T and LH levels were decreased significantly in all groups although reduction was greater in GnRH-a groups than OC alone. The reduction of free T was significantly greater with LA + OC compared with LA or OC alone. This could be a consequence of the significant rise in sex hormone-binding globulin (SHBG) in LA + OC and OC groups compared with LA in which there was no change in SHBG. Reduced facila hair density and decrease in hirsutism score was observed in both GnRH-a groups after 6 months. CONCLUSION: "Add-back" OC therapy used in combination with a GnRH-a increases SHBG and more effectively lowers free T levels in women with ovarian hyperandrogenism. Enhanced suppression of "bioavailable" androgens with combined GnRH-a and OC therapy failed to improve significantly the therapeutic effect of GnRH-a treatment alone on hirsutism.


Subject(s)
Contraceptives, Oral/therapeutic use , Hirsutism/drug therapy , Hyperandrogenism/complications , Leuprolide/therapeutic use , Ovarian Diseases/complications , Adolescent , Adult , Contraceptives, Oral/administration & dosage , Drug Therapy, Combination , Endometrium/pathology , Ethinyl Estradiol/administration & dosage , Ethinyl Estradiol/therapeutic use , Female , Hirsutism/etiology , Humans , Hyperandrogenism/pathology , Leuprolide/administration & dosage , Luteinizing Hormone/blood , Norethindrone/administration & dosage , Norethindrone/therapeutic use , Ovarian Diseases/pathology , Testosterone/blood
4.
J Clin Endocrinol Metab ; 76(2): 472-5, 1993 Feb.
Article in English | MEDLINE | ID: mdl-8432792

ABSTRACT

In this study, we report the effects of cyclic hormone replacement therapy on carbohydrate metabolism in six women with premature ovarian failure. Using tolbutamide-modified iv glucose tolerance tests patients were evaluated during three different intervals of their second treatment cycle: no hormone replacement, estradiol-only (E2-only) replacement, and E2-plus-medroxyprogesterone acetate (MPA) replacement. Insulin sensitivity and glucose effectiveness were derived using insulin and glucose levels obtained from tolbutamide-modified iv glucose tolerance tests and analyzed with the minimal model computer program. The mean insulin sensitivity (x 10(-4)/min/microU.ml) significantly decreased from 4.0 +/- 0.8 during no hormone replacement and 3.8 +/- 0.8 during E2-only replacement to 2.6 +/- 0.5 (x 10(-4)/min/microU/ml) during E2-plus-MPA replacement (P < 0.005). Glucose effectiveness did not change as a function of the phase of hormone replacement therapy. These findings indicate a significant decrease in sensitivity to insulin associated with MPA treatment but no observable change in insulin sensitivity during the E2-only phase of cyclic steroid replacement therapy in young women. Our results support the hypothesis that impairment of insulin-mediated glucose uptake during the luteal phase of the menstrual cycle is due to increased progesterone secretion.


Subject(s)
Estrogen Replacement Therapy , Insulin/pharmacology , Primary Ovarian Insufficiency/drug therapy , Adult , Blood Glucose/metabolism , Estradiol/administration & dosage , Estradiol/adverse effects , Estradiol/therapeutic use , Female , Glucose Tolerance Test , Humans , Insulin/blood , Medroxyprogesterone Acetate/administration & dosage , Medroxyprogesterone Acetate/adverse effects , Medroxyprogesterone Acetate/therapeutic use , Primary Ovarian Insufficiency/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...